文献速递疼痛医学

大麻素用于术后急性疼痛管理的镇痛疗效:系统综述与荟萃分析

Analgesic efficacy of cannabinoids for acute pain management after surgery: a systematic review and meta-analysis.
PubMed 文献 · Reg Anesth Pain Med · 2020-05-28

该系统综述与荟萃分析评估围术期大麻素化合物对术后急性疼痛的镇痛疗效,纳入8项随机对照试验(924例)和4项观察性研究(4259例)。定量合并数据不足以分析24小时累积口服吗啡当量消耗和静息疼痛严重程度;定性合成显示大麻素组与对照组无差异。大麻素组12小时疼痛评分加权均数差增加0.83 cm(95%CI 0.04至1.63,p=0.04),术后低血压风险增加3.24倍(95%CI 1.12至9.36,p=0.03)。结论认为围术期大麻素镇痛作用有限,不推荐常规使用。

要点

  • 大麻素加入传统全身镇痛药未显示临床重要获益。
  • 大麻素组12小时疼痛评分较对照组高0.83 cm(95%CI 0.04至1.63)。
  • 大麻素组术后低血压风险增加3.24倍(95%CI 1.12至9.36)。

核心结论

  • 围术期大麻素化合物的镇痛作用有限,与单纯传统全身镇痛药相比未检测到临床重要获益。
  • 结果不支持目前常规使用大麻素管理术后急性疼痛。

研究设计与样本

  • 系统综述与荟萃分析,纳入8项随机对照试验(924例患者)和4项观察性研究(4259例患者)。
  • 研究对象为术后期间在标准阿片类全身镇痛基础上加用大麻素化合物与对照的比较。

主要发现

  • 定量合并数据不足以分析24小时累积口服吗啡当量消耗和静息疼痛严重程度的差异。
  • 定性合成显示大麻素组与对照组在24小时累积口服阿片消耗或静息疼痛方面无差异。
  • 大麻素组12小时疼痛评分加权均数差增加0.83 cm(95%CI 0.04至1.63,p=0.04)。
  • 大麻素组术后低血压风险增加3.24倍(95%CI 1.12至9.36,p=0.03)。
  • 定性和定量合成显示其他次要结局无差异。

临床怎么用

  • 目前不推荐常规使用大麻素管理术后急性疼痛。
  • 围术期加用大麻素时需警惕术后疼痛加重和低血压风险。

局限性

  • 定量合并数据不足以分析主要结局(24小时累积口服吗啡当量消耗和静息疼痛严重程度)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evidence regarding the role of cannabinoids in managing acute postoperative pain is conflicting. The purpose of this systematic review and meta-analysis was to determine the analgesic efficacy of perioperative cannabinoid compounds for acute pain management after surgery. METHODS: Original research articles evaluating the addition of cannabinoids to standard opioid-based systemic analgesia (Control) in the postoperative period were sought. Our primary outcomes were cumulative oral morphine equivalent consumption and rest pain severity at 24 hours postoperatively. We also assessed analgesic consumption in the postanesthesia care unit (PACU), pain scores in PACU, 6 and 12 hours postoperatively, and opioid-related and cannabinoid-related side effects, patient satisfaction, and quality of recovery as secondary outcomes. RESULTS: Eight randomized controlled trials (924 patients) and four observational studies (4259 patients) were analyzed and included. There were insufficient data to pool for quantification of differences in cumulative oral morphine equivalent consumption and rest pain severity at 24 hours postoperatively with the addition of cannabinoids in comparison to Control. Qualitative synthesis revealed no differences in cumulative oral opioid consumption or pain at rest 24 hours postoperatively with the addition of cannabinoids in comparison to Control. Patients receiving cannabinoids appeared to have an increased weighted mean difference 95% CI of pain at 12 hours by 0.83 cm (0.04 to 1.63) (p=0.04). Patients receiving cannabinoids also appeared to have 3.24 times increased odds of developing hypotension postoperatively (95% CI 1.12 to 9.36) (p=0.03). Qualitative and quantitative synthesis revealed no differences in any other secondary outcomes. CONCLUSIONS: Our quantitative and qualitative review of the literature suggests that the analgesic role of perioperative cannabinoid compounds is limited, with no clinically important benefits detected when cannabinoids are added to traditional systemic analgesics compared with traditional systemic analgesics alone. Notably, there appears to be a signal towards increased postoperative pain and hypotension associated with the addition of perioperative cannabinoids to traditional systemic analgesics. These results do not support the routine use of cannabinoids to manage acute postoperative pain at the present time.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Abdallah FW, Hussain N, Weaver T, et al. Analgesic efficacy of cannabinoids for acute pain management after surgery: a systematic review and meta-analysis. Reg Anesth Pain Med. 2020. PMID: 32471924. doi:10.1136/rapm-2020-101340

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。